From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) have long been known as mediators of several physiological functions, among which the best characterized are lipid metabolism, energy balance and anti-inflammation. Their rather large and promiscuous ligand binding site has been recently discovered to accommodate, among a plethora of lipid molecules and metabolic intermediates, endocannabinoids and their cognate compounds, specifically belonging to the Nacylethanolamine group. In fact, oleoylethanolamide, palmitoylethanolamide and probably anandamide bind with relatively high affinity to PPARs and have now been included among their endogenous ligands. Through activation of PPARs these molecules exert a variety of physiological processes. Particularly, both long-term effects via genomic mechanisms and rapid non-genomic actions have been described, which in several instances are opposite to those evoked by activation of "classical" surface cannabinoid receptors. In this review, we describe how these effects are relevant under diverse physiological and pathophysiological circumstances, such as lipid metabolism and feeding behaviour, neuroprotection and epilepsy, circadian rhythms, addiction and cognition. A picture is emerging where nuclear receptors are involved in anorexiant, anti-inflammatory, neuroprotective, anti-epileptic, wakefulness- and cognitive-enhancing, and anti-addicting properties of endocannabinoid-like molecules. Further studies are necessary to fully understand cellular mechanisms underlying the interactions between endocannabinoids and PPARs, but also between their surface and nuclear receptors, and to exploit their potential therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 2×
“-oxidation) of fatty acids, was cloned and denominated peroxisome proliferator-activated receptor[77].”
BackgroundInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“The hydrolysis of NAEs is catalyzed by at least three enzymes: fatty acid amide hydrolase (FAAH) [52], FAAH-2 [53] and NAE-hydrolyzing acid amidase (NAAA) [54].”
BackgroundRoles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“variations of this scenario [116-119].”
Obesity-induced inflammatory changes in adipose tissue
Wellen, K. E., & Hotamisligil, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320514 · Cited by 1,823
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“Clofibrate and fenofibrate activate PPAR- with a ten-fold selectivity over PPAR- , whereas bezafibrate displays similar potency at all three PPAR isoforms [83].”
BackgroundEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“In fact, the study that shed the light into how endocannabinoids act as fast retrograde signals at the mature synapse was first carried out in the hippocampus [29], the brain area mainly involved in information storage.”
BackgroundLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559 · cited 1×
“Conversely, the CB1 antagonist rimonabant was shown to reduce feeding and body weight in experimental animals [139], and underwent clinical trials for the treatment of obesity, as well as for its beneficial effect in metabolic syndrome [140].”
BackgroundCombinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 1×
“Accordingly, AEA levels are increased within both the hippocampus of animal models of epilepsy [215, 216] and human neocortex of epileptic patients [217].”
BackgroundNongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980 · cited 1×
“A non-genomic mechanism would explain the rapid actions observed, which involve signalling pathways similar to those described for many other nuclear receptor ligands [132-134].”
BackgroundGreen, C. B., Takahashi, J. S., & Bass, J. (2008) · Cell · doi:10.1016/j.cell.2008.08.022 · Cited by 902
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
Overview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688 · cited 1×
“PPARs belong to the large superfamily of transcription factors, accounting 48 members in the human genome [73].”
BackgroundRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632 · cited 1×
“Following the cloning and characterization of CB receptors, PEA was believed to possess putative agonistic activity at CB2 receptors [152, 153] since their blockade with the selective antagonist SR144528 was found to prevent PEAinduced antinociception [153-156].”
BackgroundCannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 1×
“However, although many of cannabinoid actions are ascribed to activation of CB receptors, studies carried out in knock-out mice have disproved the involvement of these receptors solo, thus suggesting the existence of CB receptors other than CB1 and CB2 [8] and, therefore, the possibility of new targets for these lipid…”
BackgroundEndocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Nongenomic steroid action: controversies, questions, and answers
LÖSEL, R. M., FALKENSTEIN, E., FEURING, M., SCHULTZ, A., TILLMANN, H.-C., ROSSOL-HASEROTH, K., & WEHLING, M. (2003) · Physiological Reviews · doi:10.1152/physrev.00003.2003 · Cited by 561 · cited 1×
“A non-genomic mechanism would explain the rapid actions observed, which involve signalling pathways similar to those described for many other nuclear receptor ligands [132-134].”
BackgroundCannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Anticonvulsant Mechanisms of the Ketogenic Diet
Bough, K. J., & Rho, J. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00915.x · Cited by 523
Peroxisome proliferator-activated receptors: insight into multiple cellular functions
Escher, P., & Wahli, W. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00231-6 · Cited by 491 · cited 1×
“variations of this scenario [116-119].”
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Critical roles of PPARβ/δ in keratinocyte response to inflammation
Tan, N. S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Flühmann, B., Desvergne, B., & Wahli, W. (2001) · Genes & Development · doi:10.1101/gad.207501 · Cited by 398
Guzmán, M., Lo Verme, J., Fu, J., Oveisi, F., Blázquez, C., & Piomelli, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404087200 · Cited by 328
Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α
LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111385 · Cited by 316 · cited 3×
“On the other hand, NAEs significantly contribute to the antinociceptive and anti-inflammatory actions of endocannabinoids [20, 21, 30].”
BackgroundPons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J. M., Changeux, J. P., Maskos, U., & Fratta, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3918-08.2008 · Cited by 312 · cited 1×
“However, since URB597 was administered systemically, we cannot conclude that the VTA is the only brain region involved in its effects, although nicotinic receptors located on VTA dopamine cell bodies play a key role in the reinforcement properties of nicotine [238].”
BackgroundAnandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation
Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Fur, G. L., & Casellas, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.032 · Cited by 298
Nashmi, R., Xiao, C., Deshpande, P., McKinney, S., Grady, S. R., Whiteaker, P., Huang, Q., McClure-Begley, T., Lindstrom, J. M., Labarca, C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2199-07.2007 · Cited by 274
The N‐Acylethanolamine‐Hydrolyzing Acid Amidase (NAAA)
Tsuboi, K., Takezaki, N., & Ueda, N. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790159 · Cited by 172
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation
Campolongo, P., Roozendaal, B., Trezza, V., Cuomo, V., Astarita, G., Fu, J., McGaugh, J. L., & Piomelli, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903038106 · Cited by 133 · cited 6×
“Further, OEA enhances memory consolidation [26], and it has been suggested, along with PEA, to heighten memory acquisition [22].”
BackgroundInfluentialLiu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V., & Di Marzo, V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.11.047 · Cited by 115
Egertová, M., Simon, G. M., Cravatt, B. F., & Elphick, M. R. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21568 · Cited by 111
Mugnaini, M., Tessari, M., Tarter, G., Merlo Pich, E., Chiamulera, C., & Bunnemann, B. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02220.x · Cited by 88 · cited 1×
“Finally, since prolonged nicotine exposure transiently upregulates nicotinic receptors within the VTA [239-241], which play an important part in nicotine sensitization [242], and PPARactivation negatively modulates nicotinic receptors through”
BackgroundChikahisa, S., Tominaga, K., Kawai, T., Kitaoka, K., Oishi, K., Ishida, N., Rokutan, K., & Séi, H. (2008) · Endocrinology · doi:10.1210/en.2008-0285 · Cited by 57 · cited 1×
“Consistently, in another study, bezafibrate treatment was found to phase advance sleep/wake rhythm by about 2–3 h [245].”
BackgroundSleep deprivation increases oleoylethanolamide in human cerebrospinal fluid
Koethe, D., Schreiber, D., Giuffrida, A., Mauss, C., Faulhaber, J., Heydenreich, B., Hellmich, M., Graf, R., Klosterkötter, J., Piomelli, D., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0169-6 · Cited by 51
Cited by
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Bioactive Lipids and Chronic Inflammation: Managing the Fire Within
Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00038 · Cited by 427
“Besides the aforementioned CB1 and CB2 receptors, eCBs also engage other molecular targets that include members of the transient receptor potential (TRP) channels, GPR55, and peroxisome proliferator-activated receptors (PPARs), differentially expressed by body districts also according to their inflammatory state (102,…”
BackgroundCannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation
Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M., & Maccarrone, M. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.05.004 · Cited by 283
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“Other targets are peroxisome proliferator-activated receptors (PPAR) a and g (Pistis and Melis, 2010) that belong to a family of nuclear receptors whose role is mainly to control lipid metabolism; and orphan G protein-coupled receptor GPR55 (Moriconi et al., 2010).”
PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors
Scheggi, S., Melis, M., De Felice, M., Aroni, S., Muntoni, A. L., Pelliccia, T., Gambarana, C., De Montis, M. G., & Pistis, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.024 · Cited by 56
Self-citation
Metadata
- Authors
- Pistis, M., & Melis, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-05-01
- Volume
- 17
- Issue
- 14
- Pages
- 1450-1467
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2041813704
- Cited by
- 142
- References
- 48
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.